SAG 性质
| 沸点 | 688.6±55.0 °C(Predicted) |
|---|---|
| 密度 | 1.30±0.1 g/cm3(Predicted) |
| 储存条件 | Keep in dark place,Inert atmosphere,Store in freezer, under -20°C |
| 溶解度 | 可溶于 DMSO（高达 20 mg/ml）、DMF（高达 20 mg/ml）或乙醇（高达 20 mg/ml）。 |
| 酸度系数(pKa) | 10?+-.0.40(Predicted) |
| 形态 | 冻干固体 |
| 颜色 | 白色至米色 |
| 敏感性 | Light Sensitive |
| 稳定性 | 感光 |
SAG 用途与合成方法
EC50: 3 nM (Smo)
SAG (0.1 nM-100 μM; 30 h) induces firefly luciferase expression in Shh-LIGHT2 cells with an EC
50
of 3 nM and then inhibits expression at higher concentrations.
SAG (1-1000 nM; 1 h) competes for the binding of BODIPY-cyclopamine to Smo-expressing Cos-1 cells, yielding an apparent dissociation constant (K
d
) of 59 nM for the SAG/Smo complex.
SAG (100 nM) inhibits the inhibitory effect of ShhN-induced pathway activation by Robotnikinin.
SAG (250 nM; 48 h) significantly increases SMO mRNA and protein expression in MDAMB231 cells.
SAG (250 nM; 24 and 48 h) increases CAXII mRNA expression in MDAMB231 cells at 24h in normoxic and hypoxic conditions in MDAMB231 cells.
SAG (250 nM; 24 h) increases MDAMB231 cells migration.
SAG (1.0 mM) induces more osteogenesis mainly at the defect borders and a significant increase in BV/TV at the eight week timepoint in CD-1 mice.
SAG (15-20 mg/kg; i.p.) induces pre-axial polydactyly prevalently in a dose-dependent manner in mice.
| Animal Model: | Pregnant C57BL/6J mice |
| Dosage: | 15, 17, 20 mg/kg |
| Administration: | A single i.p. |
| Result: | Effective in ca. 80% of the embryos and increased Gli1 and Gli2 mRNA expression in the limb bud, with Gli1 mRNA being the most upregulated at the dose of 20 mg/kg. |
SAG 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024-11-08 | HY-12848 | SAG | 912545-86-9 | 1mg | 600 |
| 2024-11-08 | HY-12848 | SAG | 912545-86-9 | 5mg | 1800 |
